Trial Profile
Phase 2 Study of Orlistat and SLx-4090 for Teh Treatment of Type 1 Hyperlipoproteinemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs KD 026 (Primary) ; Orlistat
- Indications Hyperlipoproteinaemia type I
- Focus Therapeutic Use
- 25 Sep 2020 Status changed from active, no longer recruiting to discontinued. According to ClinicalTrials.gov, the Reason for the study was stopped: Due to unavailability of the drug.
- 04 Nov 2019 Planned End Date changed from 31 Jul 2019 to 31 Jul 2020.
- 04 Nov 2019 Planned primary completion date changed from 31 Jul 2019 to 31 Jul 2020.